Fortress Biotech, Inc. (FBIO)
NASDAQ: FBIO · IEX Real-Time Price · USD
1.750
-0.050 (-2.78%)
At close: May 3, 2024, 4:00 PM
1.830
+0.080 (4.57%)
After-hours: May 3, 2024, 6:13 PM EDT
Fortress Biotech Revenue
In the year 2023, Fortress Biotech had annual revenue of $84.51M with 11.58% growth. Revenue in the quarter ending December 31, 2023 was $19.95M with 21.59% year-over-year growth.
Revenue (ttm)
$84.51M
Revenue Growth
+11.58%
P/S Ratio
0.40
Revenue / Employee
$454,371
Employees
186
Market Cap
33.66M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 84.51M | 8.77M | 11.58% |
Dec 31, 2022 | 75.74M | 6.95M | 10.11% |
Dec 31, 2021 | 68.79M | 23.19M | 50.86% |
Dec 31, 2020 | 45.60M | 8.97M | 24.49% |
Dec 31, 2019 | 36.63M | 9.75M | 36.26% |
Dec 31, 2018 | 26.88M | 9.64M | 55.88% |
Dec 31, 2017 | 17.25M | 765.00K | 4.64% |
Dec 31, 2016 | 16.48M | 15.62M | 1,809.62% |
Dec 31, 2015 | 863.00K | - | - |
Dec 31, 2014 | 0 | - | - |
Dec 31, 2013 | 0 | - | - |
Dec 31, 2012 | 0 | - | - |
Dec 31, 2011 | 0 | - | - |
Dec 31, 2010 | 0 | - | - |
Dec 31, 2009 | 0 | - | - |
Dec 31, 2008 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Concord Medical Services Holdings | 75.80M |
Retractable Technologies | 43.60M |
CASI Pharmaceuticals | 33.88M |
Spectral AI | 18.06M |
ImmunoPrecise Antibodies | 17.67M |
Akili | 1.68M |
FBIO News
- 2 days ago - Journey Medical Corporation Appoints Joseph Benesch as Chief Financial Officer - GlobeNewsWire
- 8 days ago - Journey Medical Corporation to Present at the Planet MicroCap Showcase: Vegas 2024 - GlobeNewsWire
- 5 weeks ago - Fortress Biotech Reports 2023 Financial Results and Recent Corporate Highlights - GlobeNewsWire
- 6 weeks ago - Checkpoint Therapeutics Reports Full-Year 2023 Financial Results and Recent Corporate Highlights - GlobeNewsWire
- 6 weeks ago - Journey Medical Corporation Reports Full-Year 2023 Financial Results and Recent Corporate Highlights - GlobeNewsWire
- 6 weeks ago - Journey Medical Corporation Announces U.S. FDA Acceptance of New Drug Application for DFD-29 for the Treatment of Rosacea - GlobeNewsWire
- 7 weeks ago - Journey Medical Corporation to Announce Year End 2023 Financial Results on March 21, 2024 - GlobeNewsWire
- 7 weeks ago - Journey Medical Corporation to Participate in the 36th Annual ROTH Conference - GlobeNewsWire